Oliceridine - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for oliceridine and what is the scope of freedom to operate?
Oliceridine
is the generic ingredient in one branded drug marketed by Trevena and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Oliceridine has fifty-one patent family members in twenty-three countries.
One supplier is listed for this compound.
Summary for oliceridine
| International Patents: | 51 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 5 |
| Patent Applications: | 97 |
| What excipients (inactive ingredients) are in oliceridine? | oliceridine excipients list |
| DailyMed Link: | oliceridine at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oliceridine
Generic Entry Date for oliceridine*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for oliceridine
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Trevena Inc. | Phase 4 |
| University of Tennessee | Phase 4 |
| The Cleveland Clinic | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for oliceridine
US Patents and Regulatory Information for oliceridine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for oliceridine
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 2688403 | ⤷ Try a Trial | |
| Portugal | 3290415 | ⤷ Try a Trial | |
| Japan | 2021176885 | オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGAND AND METHODS OF USING AND MAKING THE SAME) | ⤷ Try a Trial |
| Hong Kong | 1250984 | 阿片樣物質受體配體以及使用和製備其的方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Try a Trial |
| Portugal | 2688403 | ⤷ Try a Trial | |
| Israel | 284407 | ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same) | ⤷ Try a Trial |
| Spain | 2857549 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
